SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the third quarter of 2014 and provided an update on its progress toward delivering upon its key corporate objectives and clinical development milestones.
Corporate Updates and Key Priorities for 2014/2015
As detailed in early September, following the top-line results of the COMET-1 trial in metastatic castration-resistant prostate cancer (CRPC), Exelixis initiated a significant workforce reduction in order to focus its development efforts and financial resources on the opportunities for cabozantinib in metastatic renal cell carcinoma (RCC) and advanced hepatocellular carcinoma (HCC). The company also continues to support its partner Genentech, a member of the Roche Group, as it prepares for the potential commercialization of cobimetinib, an Exelixis-discovered compound.
Help employers find you! Check out all the jobs and post your resume.
